Side-by-side · Research reference

LL-37vsMT-1

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AHuman-MechanisticHUMAN-REVIEWED15/35 cited

BFDA-ApprovedHUMAN-REVIEWED9/51 cited

LL-37

Cathelicidin · Human AMP

Broad-spectrumAntimicrobial activity

Membrane disruptionPrimary mechanismLu 2026 He 2026

Innate immunityHost defense rolePinheiro 2026 Zhang 2026

Endogenous · Secreted at inflammation sites

MT-1

α-MSH Analogue · FDA-Approved

16 mgImplant dose

13 AAPeptide lengthChawathe 2026

2019FDA approval

SQ Implant · 60-Day Release

01Mechanism of Action

Parameter

LL-37

MT-1

Primary target

Bacterial membranes · Phosphatidylserine-exposed cellsHe 2026 Lu 2026

Melanocortin-1 receptor (MC1R) on melanocytesLangan 2010

Pathway

hCAP-18 precursor → Proteinase-3 cleavage → LL-37 release → Membrane insertion/disruption

α-MSH analogue → MC1R activation → cAMP elevation → MITF transcription → eumelanin synthesis

Downstream effect

Membrane permeabilization, cytokine induction, autophagy, phagosome-lysosome fusion, chemotaxisAhmad 2026 Zhang 2026

Increased melanogenesis, photoprotection, reduced UV sensitivityLangan 2010

Feedback intact?

—

Yes — exogenous MC1R agonism does not suppress endogenous α-MSH production

Origin

Endogenous human cathelicidin (37-AA fragment, residues 134–170 of hCAP-18)

Synthetic 13-AA peptidomimetic with norleucine (position 4) and D-phenylalanine (position 7) substitutions for metabolic stabilityChawathe 2026

Antibody development

—

02Dosage Protocols

Parameter

LL-37

MT-1

Endogenous expression

Constitutive in neutrophils, epithelial tissues

Upregulated during infection and inflammation.Pinheiro 2026

—

Exogenous (experimental)

Dose varies by study; antimalarial ~10–50 μM in vitro

No FDA-approved exogenous formulation.

—

Plasma levels (malaria)

Elevated in infected patients and miceHe 2026

Exogenous administration reduced parasitemia in murine models.He 2026

—

Evidence basis

In vitro, animal models, human observational

Phase 3 RCT / FDA-approved orphan drug

Standard dose

—

16 mg subcutaneous implant

FDA-approved formulation (Scenesse).

Frequency

—

Every 60 days

Sustained release implant — no daily administration required.

Indication

—

Erythropoietic protoporphyria (EPP)

Narrow FDA approval — not licensed for cosmetic tanning.

Duration

—

Seasonal use (spring–autumn typical)

Aligned with peak UV exposure months.

Route

—

Subcutaneous implant — upper arm or abdomen

Stability

—

Norleucine/D-Phe substitutions enhance peptidase resistance

Modified structure vs endogenous α-MSH (Met⁴, L-Phe⁷).

04Side Effects & Safety

Parameter

LL-37

MT-1

Cytotoxicity (high dose)

Membrane disruption in host cells at supraphysiological concentrations

—

Pro-inflammatory signaling

Can exacerbate inflammation in certain contexts (context-dependent)Pinheiro 2026

—

Biofilm formation risk

LL-37-DNA complexes may stabilize dental plaque biofilmsTanabe 2026

—

Theoretical cancer risk

Immunomodulatory roles in tumor microenvironment under investigation

—

Nausea

—

Common (>10%) — mild, transient

Implant site reaction

—

Erythema, bruising, tenderness at insertion site

Hyperpigmentation

—

Generalised tanning (therapeutic effect), darkening of freckles/neviLangan 2010 Habbema 2017

Expected melanogenic response — complicates pigmented lesion surveillance.

Melanocytic changes

—

Rapid pigmentation of existing nevi; new melanocytic lesions reported with unregulated useHabbema 2017

Requires dermatologic monitoring; theoretical melanoma concern with chronic stimulation.

Headache

—

Occasional (MC1R-independent melanocortin effects)

Photosensitivity (paradoxical)

—

Rare phototoxic reactions despite melanin increase

Contamination risk (unregulated)

—

Impurity, infection, blood-borne virus transmission from illicit melanotan productsLangan 2010 Habbema 2017

Applies to internet/gym-sourced 'melanotan' — not FDA-approved Scenesse.

Absolute Contraindications

LL-37

—

MT-1

·Hypersensitivity to afamelanotide or excipients
·Hepatic impairment (no safety data)
·Renal impairment (no safety data)

Relative Contraindications

LL-37

·Active autoimmune disease (theoretical immune dysregulation)

MT-1

·History of melanoma or atypical nevi (melanocortin receptor stimulation concern)Habbema 2017
·Pregnancy/lactation (insufficient data)
·Photosensitive dermatoses (other than EPP)

05Administration Protocol

Parameter

LL-37

MT-1

1. Natural secretion

LL-37 is constitutively expressed in neutrophils and epithelial cells, cleaved from hCAP-18 by proteinase-3 at sites of infection or inflammation.

Performed by trained healthcare provider. Sterile technique. Small incision in upper arm (triceps) or lower abdomen using trocar. 16 mg rod (4 mm × 1.5 cm) inserted subcutaneously.

2. Experimental formulations

Synthetic LL-37 and derivatives (e.g., SAMP-12aa) tested in vitro and animal models. Administered via topical, intraperitoneal, or intravenous routes in research settings.

Pressure applied post-insertion. Sterile dressing × 24 hrs. Avoid strenuous activity for 24–48 hrs to prevent extrusion.

3. Stability considerations

LL-37 is resistant to pepsin degradation at gastric pH. Synthetic short peptides designed to retain this stability while reducing toxicity.Lu 2026

Slow biodegradable polymer matrix releases afamelanotide over 60 days, maintaining therapeutic plasma levels without daily dosing.

4. Repeat dosing

—

New implant every 60 days during high UV season (spring–autumn in temperate climates). Rotate implant sites to avoid scarring.

5. Monitoring

—

Baseline and periodic dermatologic exams to document pigmented lesions. Patient education on self-examination for new/changing nevi.